Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 183

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Clinical Role of microRNAs in Cytogenetically Normal Acute Myeloid Leukemia: miR-155 Upregulation Independently Identifies High-Risk Patients

Open access
Marcucci, Guido, Maharry, Kati S., Metzeler, Klaus H., Volinia, Stefano, Wu, Yue-Zhong, Mrózek, Krzysztof, Nicolet, Deedra, Kohlschmidt, Jessica, Whitman, Susan P., Mendler, Jason H., Schwind, Sebastian, Becker, Heiko, Eisfeld, Ann-Kathrin, Carroll, Andrew J., Powell, Bayard L., Kolitz, Jonathan E., Garzon, Ramiro, Caligiuri, Michael A., Stone, Richard M., Bloomfield, Clara D.·2013·Journal of Clinical Oncology

Abstract

Purpose: To evaluate the impact of miR-155 on the outcome of adults with cytogenetically normal (CN) acute myeloid leukemia (AML) in the context of other clinical and molecular prognosticators and to gain insight into the leukemogenic role of this microRNA. Patients and Methods: We evaluated 363 patients with primary CN-AML. miR-155 levels were measured in pretreatment marrow and blood by NanoString nCounter assays that quantified the expression of the encoding gene MIR155HG. All molecular prognosticators were assessed centrally. miR-155–associated gene and microRNA expression profiles were derived using microarrays. Results: Considering all patients, high miR-155 expression was associated with a lower complete remission (CR) rate (P < .001) and shorter disease-free survival (P = .001) and overall survival (OS; P < .001) after adjusting for age. In multivariable analyses, high miR-155 expression remained an independent predictor for a lower CR rate (P = .007) and shorter OS (P < .001). High miR-155 expressers had approximately 50% reduction in the odds of achieving CR and 60% increase in the risk of death compared with low miR-155 expressers. Although high miR-155 expression was not associated with a distinct microRNA expression profile, it was associated with a gene expression profile enriched for genes involved in cellular mechanisms deregulated in AML (eg, apoptosis, nuclear factor-κB activation, and inflammation), thereby supporting a pivotal and unique role of this microRNA in myeloid leukemogenesis. Conclusion: miR-155 expression levels are associated with clinical outcome independently of other strong clinical and molecular predictors. The availability of emerging compounds with antagonistic activity to microRNAs in the clinic provides the opportunity for future therapeutic targeting of miR-155 in AML.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2012.45.6228

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 183

Metadata

Authors
Marcucci, G., Maharry, K. S., Metzeler, K. H., Volinia, S., Wu, Y.-Z., Mrózek, K., Nicolet, D., Kohlschmidt, J., Whitman, S. P., Mendler, J. H., Schwind, S., Becker, H., Eisfeld, A.-K., Carroll, A. J., Powell, B. L., Kolitz, J. E., Garzon, R., Caligiuri, M. A., Stone, R. M., & Bloomfield, C. D.
Venue
Journal of Clinical Oncology
Published
2013-06-10
Volume
31
Issue
17
Pages
2086-2093
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2167584976
Cited by
183
References
4
FWCI
18.34
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical Role of microRNAs in Cytogenetically Normal Acute Myeloid Leukemia: miR-155 Upregulation Independently Identifies High-Risk Patients. https://app.cochat.ai/papers/10.1200/jco.2012.45.6228
The paper
Marcucci, G., Maharry, K. S., Metzeler, K. H., Volinia, S., Wu, Y.-Z., Mrózek, K., Nicolet, D., Kohlschmidt, J., Whitman, S. P., Mendler, J. H., Schwind, S., Becker, H., Eisfeld, A.-K., Carroll, A. J., Powell, B. L., Kolitz, J. E., Garzon, R., Caligiuri, M. A., Stone, R. M., & Bloomfield, C. D. (2013). Clinical Role of microRNAs in Cytogenetically Normal Acute Myeloid Leukemia: miR-155 Upregulation Independently Identifies High-Risk Patients. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2012.45.6228

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.